--- title: "Shenqi (900904.SH)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/900904.SH.md" symbol: "900904.SH" name: "Shenqi" industry: "Pharmaceuticals" --- # Shenqi (900904.SH) | Item | Detail | |------|--------| | Industry | Pharmaceuticals | ## Company Profile Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumati... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-20T04:30:10.000Z **Overall: C (0.45)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 178 / 222 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -14.92% | | | Net Profit YoY | 22.55% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 0.81 | | | Dividend Ratio | 4.08% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1.89B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 1.80B | | **Multi Score**: C #### Profit Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 2.66% | C | | Profit Margin | 3.31% | C | | Gross Margin | 49.36% | B | #### Growth Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -14.92% | E | | Net Profit YoY | 22.55% | B | | Total Assets YoY | -5.36% | D | | Net Assets YoY | -2.06% | D | #### Cash Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 3021.37% | A | | OCF YoY | -14.92% | E | #### Operating Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.60 | B | #### Debt Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 21.93% | A | ```chart-data:radar { "title": "Longbridge Financial Score - Shenqi", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "C", "indicators": [ { "name": "ROE", "value": "2.66%", "rating": "C" }, { "name": "Profit Margin", "value": "3.31%", "rating": "C" }, { "name": "Gross Margin", "value": "49.36%", "rating": "B" } ] }, { "name": "Growth", "grade": "D", "indicators": [ { "name": "Revenue YoY", "value": "-14.92%", "rating": "E" }, { "name": "Net Profit YoY", "value": "22.55%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-5.36%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-2.06%", "rating": "D" } ] }, { "name": "Cash", "grade": "C", "indicators": [ { "name": "Cash Flow Margin", "value": "3021.37%", "rating": "A" }, { "name": "OCF YoY", "value": "-14.92%", "rating": "E" } ] }, { "name": "Operating", "grade": "B", "indicators": [ { "name": "Turnover", "value": "0.60", "rating": "B" } ] }, { "name": "Security", "grade": "A", "indicators": [ { "name": "Gearing Ratio", "value": "21.93%", "rating": "A" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Allist (SH.688578) | A | A | B | A | B | A | | 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A | | 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B | | 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B | | 05 | Salubris (SZ.002294) | B | B | C | A | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 30.25 | 72/222 | 33.83 | 31.22 | 30.31 | | PB | 0.81 | 3/222 | 0.87 | 0.84 | 0.81 | | PS (TTM) | 1.00 | 7/222 | 1.05 | 1.01 | 0.97 | | Dividend Yield | 4.08% | 12/222 | 4.10% | 4.00% | 2.80% | ## References - [Company Overview](https://longbridge.com/en/quote/900904.SH/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/900904.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/900904.SH/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.